期刊文献+

美国药品审评创仿平衡机制研究 被引量:11

Balance Mechanism Study between Brand-Name Drugs and Generic Drugs in American Drug Review
原文传递
导出
摘要 目的探索美国药品审评创仿平衡机制。方法通过查阅美国法律法规及国内外文献,追溯仿制药发展的基础和原研药企业阻止仿制药竞争的行动,并由此归纳美国为维持药品审评创仿平衡稳定性采取的调整措施。结果与结论《药品价格竞争与专利期补偿法》中的简略新药申请、专利挑战制度以及首仿药市场独占制度构成仿制药发展的基础。原研药企业则通过提前抢占市场、拒绝提供研究用样品、提交公民请愿书延长仿制药审评时间及延长原研药专利期和市场独占期阻止仿制药竞争。美国通过立法、修订法律法规、调整仿制药企业收费政策等方式维持创仿平衡的稳定性,值得我国深入学习和研究。 OBJECTIVE To figure out the balance mechanism between brand-name drugs and generic drugs in American drug review. METHODS This paper reviewed FDA laws and regulations, domestic and foreign literature to retrospect the basis of generic development and explore the brand-name drug companies' action to prevent generic competition. RESULTS AND CONCLUSION The abbreviate new drug application, patent challenge and market exclusivity in the Hatch-Waxman Act were the basis of generic development. Brand-name drug companies prevented competition by occupying the market, refusing to provide samples, submitting citizen petitions to extend generic drug review time and extending the patent term and market exclusivity of brand-name drugs. The United States legislated and amended relevant laws and regulations, adjusted the generic drug user fee to maintain the stability of the balance, which is worthy of further research.
作者 冯霄婵 杨悦 FENG Xiao-chan;YANG Oue(Business Administration School , Shenyang Pharmaceutical University, Shenyang 110016, China;International Food and Drug Policy and law Center, Shenyang 110016, China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2018年第11期938-944,共7页 Chinese Pharmaceutical Journal
基金 国家食品药品监督管理总局课题项目资助(20170011) 工业和信息化部产业发展促进中心课题项目资助(2017021)
关键词 创仿平衡 药品价格竞争与专利期补偿法 专利挑战制度 balance mechanism between brand-name drug and generic drug Hatch-Waxman Act. patent challenge
  • 相关文献

参考文献2

二级参考文献42

  • 1Ken Krizner.Major Brand-name Drugs Face Patent Expiration[N/OL].[2011-12-10].http://drugtopics.modernmedicine.com/drugtopics/Modem +Medicine + Now/Major-brand-name-drugs-face-patent-expiration/ArticleStandard/Article/detail/711836.
  • 2Big Pharma's 2009-2013 Patent Cliff[R/OL].[2011-12-10].http://aladinrc.wrlc.org/bitstream/1961/9359/1/Jardines,%20Ben% 20-% 20Spring% 20 10% 20(P).pdf.
  • 3Catherine Zielinski.Patent Myths[EB/OL].[2011-11-23].http://info.Articleonepartners.Com/blog/bid/55616/Top-5-Patent-Myths.
  • 4FDA,Letter to Stuart A.Williams(Mylan Pharmaceuticals)and James N.Czaban(Heller Ehrman),RE:Docket Nos[EB/OL].[2011-12-8].http:// www.fda.gov/ohrms/DOCKETS/dailys/04/july04/070704/04p-0075-pdn0001.pdf.
  • 5Notice of Authorized Generic Drug Study[R/OL].[2011-12-8].http://www.ftc.gov/os/2006/03/P062105Authorized GenericDrugStudyFRNotice.pdf.
  • 6John R,Thomas.Authorized Generic Pharmaceuticals:Effects on Innovation[R].CRS Report for Congress,August 8,2006;January 10,2008.
  • 7IMS CONSULTING.Report to PhRMA:Assessment of Authorized Generics in the U.S.[R] ,2006.
  • 8Ernst R,Berndt,et al.Authorized Generic Drugs,Price Competition,And Consumers' Welfare[J].Health Affairs,2007,26(3):790.
  • 9Hollis A.The Anti-competitive Effects of Brand-Controlled "Pseudo-Generics" in the Canadian Pharmaceutical Market[J].Canadian Public Policy/Analyse de Politiques,2003,29(1):21.
  • 10Grabowski H,Vernon J.Brand Loyalty,Entry,and Price Competition in Pharmaceuticals After the 1984 Drug Act[J].Journal of Law and Economics,1992,35:331-51.

共引文献14

同被引文献110

引证文献11

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部